NEW YORK, April 25, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced presentations highlighting data from the ULTIMATE I...
All Patients in Three BX1000 Treatment Cohorts Met Criteria for Good or Excellent Intubation Conditions at 60 Seconds Results to...
First-ever orphan drug designation for genetically modified gamma-delta T cell therapiesThis orphan drug designation offers potential 7-year market exclusivity for...
New role supports the Company’s objective to lead the industry with faster, more inclusive clinical researchRESEARCH TRIANGLE PARK, N.C., April...
WATERTOWN, Mass., April 25, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology...
Carlsbad, California, April 25, 2023 (GLOBE NEWSWIRE) -- Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV:ASG) (OTCQB: ASAPF), a...
SAN DIEGO, April 25, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a...
NEW YORK, April 25, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage...
WARMINSTER, Pa., April 25, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical...
ATSN-101 demonstrated clinically meaningful improvements in vision at the highest dose with no drug-related serious adverse events 6 months post...
Breakthrough platform creating multi-valent and multi-specific biotherapeutics with broad transformative applications Building innovative internal pipeline in oncology TORONTO, April 25,...
BOSTON and GENEVA, Switzerland, April 25, 2023 (GLOBE NEWSWIRE) -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the...
Three U.S. clinical trial sites actively screening and enrolling patientsTop line data of adrulipase in Cystic Fibrosis patients expected in...
CAMBRIDGE, Mass., April 25, 2023 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular...
- Patent broadly covers technology to select neoantigens that are presented by HLA molecules determined to be present in a...
BOSTON, April 25, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the...
Montauk Brings Local Flavor to The K Korner at Citi Field with Fan-Favorite Montauk Brewing Signature Craft Beers Montauk Brewing...
Virtual event on Tuesday, May 2, 2023 at 11:00am ET will feature key opinion leader (KOL) Larry Ereshefsky, PharmD, BCPP,...
On track for initial readouts in Q2 2023 from ongoing Phase 1 VYD222 clinical trial being conducted in Australia, with...
-MORF-057 demonstrates statistically significant reduction of 6.4 points (p=0.002) from baseline at Week 12 in the Robarts Histopathology Index (RHI)...